Navigation Links
SkinMedica to Co-Promote ACZONE(R) (dapsone) Gel 5% to Pediatricians in the U.S.

ACZONE(R) Gel 5% is the First New FDA-Approved Chemical Entity for Topical Acne Treatment in a Decade

CARLSBAD, Calif., May 11 /PRNewswire/ -- SkinMedica, Inc. today announced that it has entered into a co-promotion agreement with Allergan for ACZONE(R) (dapsone) Gel 5%, a first-in-class topical treatment for acne vulgaris. Representing the first new molecule in a decade approved by the FDA for the topical treatment of acne in patients 12 years of age and older, ACZONE(R) Gel 5% combines dapsone in a Solvent Microparticulate(TM)gel, enabling dapsone to be applied topically in a well-tolerated formulation to provide patients with a convenient and effective therapy. Under the agreement, SkinMedica will exclusively promote ACZONE(R) Gel 5% to pediatricians in the United States through its existing sales force.

"We are delighted to add ACZONE(R) Gel 5% to our dermatology consultations with pediatricians, as it provides us with a pivotal opportunity to further educate pediatricians regarding the latest advancements in acne treatment," said Mary Fisher, President and CEO of SkinMedica. "This co-promotion agreement expands the portfolio of products SkinMedica can now offer pediatricians, enabling us to further meet the demands of physicians and patients across the country."

Allergan will continue to distribute the product, and its dermatology sales force will continue to promote the product. Allergan will book all ACZONE(R) Gel 5% sales and SkinMedica will receive a share of sales above a pre-specified baseline. There are no upfront payments by either party.

About Acne

Acne vulgaris, or acne, is a common skin disorder with an estimated 80 percent of all people between the ages of 11 and 30 years old experiencing outbreaks at some point. Acne treatment depends on whether a patient has a mild, moderate, or severe form. Fortunately, acne is also one of the most treatable skin conditions once a physician and patient find an appropriate product and dosage.

About ACZONE(R) Gel 5%

ACZONE(R) Gel 5% is an aqueous topical gel formulation containing 5% dapsone. Marketed by Allergan, it was developed by QLT Inc.'s wholly owned subsidiary, QLT USA, Inc., for the treatment of acne vulgaris. Combining dapsone in a Solvent Microparticulate(TM) gel enables dapsone to be applied topically. ACZONE(R) Gel 5% was originally approved by the U.S. Food and Drug Administration (FDA) in July 2005 and by Health Canada in June 2006. On March 17, 2008 and June 5, 2008 the FDA and Health Canada, respectively, removed certain restrictive requirements from the ACZONE(R) Gel 5% label. The most common adverse events reported with ACZONE(R) Gel 5% in controlled clinical trials included oiliness/peeling, dryness, and erythema. There were no significant differences in the adverse event rates between ACZONE(R) Gel 5% and vehicle-control-treated patients.

Important Safety Information

Warnings and Precautions

Hemotological effects: Oral dapsone treatment has produced dose-related hemolysis and hemolytic anemia. Individuals with glucose-6-phosphate dehydrogenese (G6PD) deficiency are more prone to hemolysis with the use of certain drugs. There was no evidence of clinically relevant hemolysis or anemia in patients treated with ACZONE(R) Gel 5%, including patients who were G6PD deficient. Some subjects with G6PD deficiency using ACZONE(R) Gel 5% developed laboratory changes suggestive of mild hemolysis.

If signs and symptoms suggestive of hemolytic anemic occur, ACZONE(R) Gel 5% should be discontinued. ACZONE(R) Gel 5% should not be used in patients who are taking oral dapsone or anti-malarial medications because of the potential for hemolytic reactions. Combination of ACZONE(R) Gel 5% with trimethroprim/sulfamethoxazole (TMP/SMX) may increase the likelihood of hemolysis in patients with G6PD deficiency.

Peripheral neuropathy: Peripheral neuropathy (motor loss and muscle weakness) has been reported with oral dapsone treatment. No events of peripheral neuropathy were observed in clinical trials with topical ACZONE(R) Gel 5% treatment.

Skin: Skin reactions (toxic epidermal necrolysis, erythema multiforme, morbiliform and scarlatiniform reactions, bullous and exfoliative dermatitis, erythema nodosum, and urticaria) have been reported with oral dapsone treatment. These types of skin reactions were not observed in clinical trials with ACZONE(R) Gel 5% treatment.


The most common adverse reactions of ACZONE(R) Gel 5% (incidence is greater than or equal to 10%) are oiliness/peeling, dryness, and erythema at the application site.

For full prescribing information go to and

About SkinMedica

SkinMedica, Inc. is focused on developing, acquiring and commercializing products that treat dermatologic conditions and improve the appearance of skin. We market and sell primarily to dermatologists and pediatricians, both prescription pharmaceutical products and physician-dispensed, non-prescription skin care products. SkinMedica's pharmaceutical products include Desonate(R) (desonide) Gel 0.05% for the treatment of mild to moderate atopic dermatitis; VANIQA(R) (eflornithine hydrochloride) Cream, 13.9%, the only FDA-approved prescription product for the treatment of unwanted facial hair in women; and EpiQuin(R) Micro Cream (4% hydroquinone) for the treatment of melasma and post-inflammatory hyperpigmentation.

NeoBenz(R) Micro Wash Plus Pack, NeoBenz(R) Micro Cream Plus Pack, and NeoBenz(R) Micro SD all incorporate the patented gradual-release MICROSPONGE(R) delivery system of benzoyl peroxide, for the treatment of acne in patients 12 years of age and older.

The company's full line of aesthetic products includes the revolutionary TNS Essential Serum(TM) and hallmark TNS Recovery Complex(R). The formulations in our clinical skin care collection enhance skin appearance, reduce signs of aging and provide other skin care benefits. SkinMedica is based in Carlsbad, California. For more information, visit:

Desonate(R), EpiQuin(R) Micro, NeoBenz(R) Micro, SkinMedica(R), TNS Recovery Complex(R) and VANIQA(R) are registered trademarks of SkinMedica, Inc and affiliates.

    Ted Ebel
    Vice President, Corporate Development
    (760) 448-3620

SOURCE SkinMedica, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. SkinMedica(R) Launches NeoBenz(R) Micro Wash for Acne
2. SkinMedica Launches On-Line Service for Physician Partners
3. SkinMedica Hosts Aesthetics Division National Sales Meeting
4. SkinMedica(R) Launches New Informational Web Site
5. GlaxoSmithKline and Shire Enter Agreement to Co-Promote Vyvanse(R) (lisdexamfetamine dimesylate) CII for Adult Attention Deficit Hyperactivity Disorder
6. Nations #1 Respiratory Hospital Enters Agreement to Co-Promote IgE Blood Testing
7. QLT announces agreement to sell Aczone(R) to Allergan for approximately US$150 million
8. American College of Pediatricians: Another Blow to Childrens Rights
9. Survey could help pediatricians better treat patients
10. Pediatricians Could Help Screen for Alcohol Abuse in Home
11. Parents comfortable with alcohol screening in pediatricians offices
Post Your Comments:
(Date:11/30/2015)... Los Angeles, CA (PRWEB) , ... November 30, 2015 , ... ... music star Jessie James Decker made a brave but slightly unusual choice to show ... quickly returning to her pre-pregnancy form may have been pre-mature. Saying that she didn’t ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... education course in Dallas, TX, on January 29 and 30, 2016. The course ... the functions of their practices, to learn how to better succeed in the ...
(Date:11/30/2015)... ... November 30, 2015 , ... RoamRight, a leading provider of travel insurance ... Television’s Travel With Kids to promote family vacations around the world. The television ... international destinations and educate families about the people and places of the world, all ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... up by athletic teams looking to maximize recovery through quality sleep. Tim DiFrancesco, ... and consistently get a better night’s sleep. ChiliPad precisely regulates the surface temperature ...
(Date:11/30/2015)... ... November 30, 2015 , ... Using a combination of two blood sugar tests ... adults, according to a new study by researchers at the School of Public Health ... Adults: Using Combinations of Blood Glucose Tests ,” published in Frontiers in Public Health, ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... , November 30, 2015 /PRNewswire/ ... --> adds a ... for 2010 - 2015 with comprehensive ... a range of deal types, such ... strategic alliances. ...
(Date:11/30/2015)... Diagnostics, the U.S.-based manufacturer of point-of-care biometric testing devices ... systems, and PTS Detect™ cotinine systems, has announced the ... the company into the mHealth market. ... The technology is a system that interfaces with mobile ... and uses test strip technology already developed by PTS ...
(Date:11/30/2015)... , Nov. 30, 2015 iCAD, Inc. ... will feature its latest solutions for advanced image ... of cancer at the Radiological Society of North ... Chicago from November 29 to December ... advances including iReveal®, an automated breast density assessment ...
Breaking Medicine Technology: